SCHEMBL5047091

SCHEMBL5047091

CC1(C)CCC(C)(C)c2c(CCc3ccc(F)cc3)cc(C(=O)/C=C/c3ccc(C(=O)O)cc3)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 10/20 0.48
RARB P10826 10/20 0.48
RARG P13631 10/20 0.48
CYP26A1 O43174 2/20 0.43
TNFRSF1A P19438 1/20 0.43
RXRA P19793 8/20 0.42
RXRB P28702 3/20 0.42
RXRG P48443 3/20 0.42
MAOB P27338 2/20 0.41
TP53 P04637 2/20 0.41
CYP3A4 P08684 2/20 0.41
BLM P54132 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047093 1.00 RARA (0.48) RARARARBRARGCYP26A1TNFRSF1A
SCHEMBL5048439 0.91 RARA (0.48) RARARARBRARGCYP26A1RXRA
SCHEMBL5048438 0.91 RARA (0.48) RARARARBRARGCYP26A1RXRA
SCHEMBL5050675 0.89 RARA (0.46) RARARARBRARGCYP26A1RXRA
SCHEMBL5050685 0.89 RARA (0.46) RARARARBRARGCYP26A1RXRA
SCHEMBL5047072 0.85 RARA (0.45) RARARARBRARGCYP26A1TNFRSF1A
SCHEMBL5050768 0.85 TP53 (0.47) RARARARBRARGCYP26A1TNFRSF1A
SCHEMBL5050773 0.85 TP53 (0.47) RARARARBRARGCYP26A1TNFRSF1A
SCHEMBL5047126 0.83 RARB (0.48) RARARARBRARGCYP26A1TNFRSF1A
SCHEMBL5047125 0.83 RARB (0.48) RARARARBRARGCYP26A1TNFRSF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US claimed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US claimed
EP-1513803-A1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS Galderma Research & Development, S.N.C. (FR) 2005-03-16 EP claimed
WO-2003101945-A1 LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2003-12-11 WO claimed
US-7326803-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-02-05 US disclosed
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148670-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARA 1/4885RARB 2/4885RARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.